Literature DB >> 1836481

Production of IL-1 receptor antagonist by human in vitro-derived macrophages. Effects of lipopolysaccharide and granulocyte-macrophage colony-stimulating factor.

R W Janson1, K R Hance, W P Arend.   

Abstract

The objective of these experiments was to evaluate the production of IL-1ra, a specific receptor antagonist of IL-1, by human in vitro-derived macrophages, a model for differentiated macrophages. IL-1ra protein levels in supernatants and lysates of cultured cells were determined by a specific ELISA. Relative steady-state IL-1ra mRNA levels were measured using a specific cDNA probe. Human monocytes were differentiated by 6 days culture in either medium or granulocyte-macrophage colony-stimulating factor (GM-CSF), after which the effects of subsequent LPS and/or GM-CSF on the production of IL-1ra were evaluated. In vitro-derived macrophages cultured in medium for 6 days constitutively produced IL-1ra protein during the 24-h period of the 7th day in culture. The constitutive production of IL-1ra by medium-aged cells correlated with low steady-state IL-1ra mRNA levels determined over this same time period. In contrast, cells cultured for 6 days in GM-CSF synthesized significantly increased levels of IL-1ra protein during the 7th day in culture but the secreted levels remained unchanged. Cells differentiated in GM-CSF displayed enhanced steady-state levels of IL-1ra mRNA in comparison with cells aged in medium. Stimulation of in vitro-derived macrophages aged for 6 days in medium or in GM-CSF, with LPS or adherent IgG, did not result in increased levels of IL-1ra protein production in comparison with non-LPS stimulated cells. The IL-1ra protein detected in the supernatants of cells differentiated in GM-CSF was biologically active in the IL-1-augmented murine thymocyte proliferation assay. By Western blot analysis, the IL-1ra protein in the in vitro-derived macrophage supernatants was predominantly the 22- to 24-kDa glycosylated species, whereas the lysates contained additional lower molecular weight forms. These results suggest that as monocytes differentiate in vitro into macrophages, they constitutively produce IL-1ra protein and that this production is enhanced by the continuous presence of GM-CSF.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1836481

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis.

Authors:  M Cutolo; A Sulli; C Pizzorni; B Seriolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

2.  Revision joint replacement, wear particles, and macrophage polarization.

Authors:  Allison J Rao; Emmanuel Gibon; Ting Ma; Zhenyu Yao; R Lane Smith; Stuart B Goodman
Journal:  Acta Biomater       Date:  2012-04-03       Impact factor: 8.947

3.  Modulation of dendritic cells using granulocyte-macrophage colony-stimulating factor (GM-CSF) delays type 1 diabetes by enhancing CD4+CD25+ regulatory T cell function.

Authors:  Donald Cheatem; Balaji B Ganesh; Eryn Gangi; Chenthamarakshan Vasu; Bellur S Prabhakar
Journal:  Clin Immunol       Date:  2009-01-25       Impact factor: 3.969

4.  Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice.

Authors:  Carole Dumas; Anthony Muyombwe; Gaétan Roy; Claudine Matte; Marc Ouellette; Martin Olivier; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

5.  Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients.

Authors:  Sebastian Niedźwiecki; Tomasz Stepień; Krzysztof Kuzdak; Henryk Stepień; Roman Krupiński; Daniel Seehofer; Nada Rayes; Frank Ulrich
Journal:  Langenbecks Arch Surg       Date:  2007-12-07       Impact factor: 3.445

6.  Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD).

Authors:  S Dionne; I D D'Agata; J Hiscott; T Vanounou; E G Seidman
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

7.  Peripheral blood neutrophil production of interleukin-1 receptor antagonist and interleukin-1 beta.

Authors:  M Malyak; M F Smith; A A Abel; W P Arend
Journal:  J Clin Immunol       Date:  1994-01       Impact factor: 8.317

8.  Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas.

Authors:  Jane R Engler; Aaron E Robinson; Ivan Smirnov; J Graeme Hodgson; Mitchel S Berger; Nalin Gupta; C David James; Annette Molinaro; Joanna J Phillips
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

9.  Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses.

Authors:  Philip T Liu; Mirjam Schenk; Valencia P Walker; Paul W Dempsey; Melissa Kanchanapoomi; Matthew Wheelwright; Aria Vazirnia; Xiaoran Zhang; Andreas Steinmeyer; Ulrich Zügel; Bruce W Hollis; Genhong Cheng; Robert L Modlin
Journal:  PLoS One       Date:  2009-06-05       Impact factor: 3.240

10.  Interleukin (IL) 4 differentially regulates monocyte IL-1 family gene expression and synthesis in vitro and in vivo.

Authors:  H L Wong; G L Costa; M T Lotze; S M Wahl
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.